Fairview Health Services
Fairview Health Services was paid $29.98M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is 99285, emergency room visit (most serious) — 44% of everything it billed.
BURNSVILLE, MN 55337
Next to other Clinical Pathology/Laboratory Medicine Physician providers in Minnesota
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,415 | $1.72M | |
| 2019 | 48,140 | $4.67M | |
| 2020 | 31,324 | $3.30M | |
| 2021 | 46,700 | $4.59M | |
| 2022 | 64,283 | $6.06M | |
| 2023 | 57,336 | $5.51M | |
| 2024incomplete | 37,568 | $4.13M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 44% | 37,623 | 34,927 | $13.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 30,889 | 29,694 | $5.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 20,427 | 19,483 | $5.24M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 12,700 | 11,638 | $1.45M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.4% | 7,889 | 7,725 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 9,744 | 8,568 | $711K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 32,111 | 28,218 | $454K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 16,302 | 14,422 | $325K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,271 | 3,100 | $278K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 509 | 445 | $207K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,411 | 1,384 | $170K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,916 | 8,619 | $149K |
73 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,129 | $135K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,981 | $110K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,191 | $100K |
| 80053 | Comprehensive metabolic panel | <1% | 13,460 | $73K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 742 | $66K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 681 | $60K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 260 | $57K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 821 | $55K |
| G0378 | Hospital observation service, per hour | <1% | 399 | $54K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 768 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 50,640 | $46K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 615 | $45K |
| 99223 | Prolong inpt eval add15 m | <1% | 292 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,157 | $31K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 660 | $29K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 606 | $28K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 272 | $25K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 271 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 78 | $19K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 405 | $15K |
| 99220 | <1% | 126 | $15K | |
| J3490 | Unclassified drugs | <1% | 73 | $13K |
| 81001 | <1% | 12,077 | $13K | |
| 84484 | <1% | 5,439 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 148 | $9K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,935 | $8K |
| 92015 | Determination of refractive state | <1% | 317 | $7K |
| 88307 | <1% | 53 | $5K | |
| 99217 | <1% | 112 | $5K | |
| A9270 | Non-covered item or service | <1% | 3,191 | $5K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 105 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,305 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,038 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 34 | $3K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 33 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 175 | $2K |
| 83690 | <1% | 2,022 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 131 | $2K |
| 84703 | <1% | 594 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,695 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $1K |
| 76820 | <1% | 39 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,632 | $908.01 |
| 99460 | <1% | 12 | $875.40 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 264 | $871.11 |
| 85027 | <1% | 978 | $738.47 | |
| 80076 | <1% | 38 | $685.78 | |
| 92060 | <1% | 14 | $653.10 | |
| 84702 | <1% | 583 | $568.61 | |
| 97803 | <1% | 29 | $527.77 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $310.31 |
| 85610 | <1% | 49 | $265.22 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 306 | $181.60 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 460 | $150.40 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,360 | $117.81 |
| 83735 | <1% | 129 | $113.63 | |
| 83605 | <1% | 183 | $109.61 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 411 | $104.64 |
| 81025 | <1% | 51 | $74.18 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 933 | $71.06 |
| 82077 | <1% | 12 | $37.37 | |
| 83880 | <1% | 14 | $34.07 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 473 | $19.22 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 290 | $18.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 35 | $13.80 |
| 82962 | <1% | 198 | $11.31 | |
| 85379 | <1% | 12 | $7.49 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 29 | $0.99 |
| J2704 | Injection, propofol, 10 mg | 0% | 15 | $0.00 |
| 87081 | 0% | 137 | $0.00 | |
| 87807 | 0% | 13 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 197 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Fairview Health Services | Minneapolis, MN | $90.41M |
| Fairview Health Services | Saint Paul, MN | $48.52M |
| Fairview Health Services | Minneapolis, MN | $26.56M |
| Healtheast ST. John's Hospital | Maplewood, MN | $17.91M |
| Fairview Health Services | Edina, MN | $17.24M |
| Healtheast Medical Research Institute | Saint Paul, MN | $11.37M |
| Fairview Clinics | Bloomington, MN | $9.40M |
| Fairview Health Services | Princeton, MN | $9.36M |
| Healtheast Medical Research Institute | Saint Paul, MN | $8.76M |
| Healtheast Medical Research Institute | Saint Paul, MN | $8.29M |
| Fairview Clinics | Brooklyn Park, MN | $8.06M |
| Fairview Health Services | Wyoming, MN | $7.71M |
| Healtheast Medical Research Institute | Maplewood, MN | $7.44M |
| Healtheast Woodwinds Hospital | Woodbury, MN | $6.17M |
| Fairview Clinics | Burnsville, MN | $4.75M |
| Fairview Clinics | Minneapolis, MN | $4.75M |
| Fairview Express Care | Saint Paul, MN | $4.57M |
| Fairview Clinics | Saint Paul, MN | $4.37M |
| Healtheast Medical Research Institute | Woodbury, MN | $4.07M |
| Fairview Clinics | Princeton, MN | $4.05M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.